J. Auton. Pharmac. (1989), **9**, 429–431

Author Index

Abelli L., Somma V., Maggi C.A., Regoli D., Astolfi M., Parlani M., Rovero P., Conte B. & Meli A.: Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NK–1 receptors, 253
Adler–Graschinsky E., Elgoyhen A.B. & Butta N. V.: Different receptor subtypes mediate the dual presynaptic effects of 5-hydroxytryptamine on peripheral sympathetic neurones, 3
Astolfi M., *see* Abelli L.
Auget M., *see* Delaflotte S.

Badia A., *see* Cuffi M.L.
Bagdy G., *see* Szemeredi K.
Ball S. G., *see* Stott D.J.
Barbier A.J., Guenaneche F. & Lefebvre R.A.: Influence of GABA and ethylenediamine in the guinea-pig duodenum, 279
Barr S.M., *see* Elfellah M.S.
Beck K.: Autonomic control of secretion of gastric acid and pepsin, 419
Bennett L., Papa A., Naruse S. & Magee D.F.: Isoprenaline and the pancreas in dogs, 379
Bond R.A., Craig D.A., Charlton K.G., Ornstein A.G. & Clarke D.E.: Partial agonistic activity of GR43175 at the inhibitory prejunctional 5-HT_1-like receptor in rat kidney, 201
Boura A.L.A., *see* Jansakul C.
see also Rose' Meyer C.M.
Braquet P., *see* Delaflotte S.
Brown M.D.: Myocardial chronotropic and inotropic responsiveness *in vitro* after chronic α-adrenoreceptor blockade in the rat, 387
Butta N.V., *see* Adler-Graschinsky E.

Cavero I., *see* Lawson K.
Charlton K.G., *see* Bond R.A.
Clarke D.E., *see* Bond R.A.
Clostre F., *see* Delaflotte S.
Conte B., *see* Abelli L.
Conti S., *see* Maggi C.A.
Craig D.A., *see* Bond R.A.
Cuffi M.L., Vila E. & Badia A.: Effects of some antipsychotic drugs on cardiovascular catecholamine receptors in the rat, 397

de Groat W.D., *see* Theobald R.J. Jr
Delaflotte S., Auguet M., Pirotzky E., Clostre F. & Braquet P.: Effects of atrial natriuretic factor (ANF) on phenylephrine-triggered intra- and extracellular calcium dependent contraction in rat aorta, 211
Doggrell S.A.: The effects of β-adrenoreceptor antagonists on the force responses of the electrically driven rat right ventricle strip to isoprenaline, 265
Dowding T., *see* Rand M.J.
Draper A.J., Meghji S. & Redfern P.H.: Enhanced presynaptic facilitation of vascular adrenergic neurotransmission in spontaneously hypertensive rats, 103
Drew G.M., *see* Gurden J.M.

Elfellah M.A., Hamilton C.A., McIntosh W., Barr S.M., Howie C. & Reid J.L.: Skeletal muscle β_2-adrenoreceptors and the effect of adrenergic drugs on plasma potassium in perinephritis hypertension in rabbits, 113
Elgoyhen A.B., *see* Adler-Graschinsky E.

Fekete M.I.K., *see* Szemeredi K.
Folly G., *see* Lonart G.

Giulianai S., *see* Maggi C.A.
Golenhofen K., *see* Ludtke F.E.
Guenaneche F., *see* Barbier A.J.
Gurden J.M., Apperley G.H. & Drew G.M.: A comparison of the properties of prenalterol and corwin at β_1- and β_2-adrenoreceptors *in vitro*, 79

Hamilton C.A., *see* Elfellah M.A.
Harsing L.G. Jr, *see* Lonart G.
Hieble J P., *see* Willette R.N.
Hodsman G.P., *see* Howes L.G.
Howes L.G., Hodsman G.P., Rowe P.R., Sumithran E. & Johnston C.I.: Cardiac 3,4-dihydroxyphenylethylene glycol (DHPG) and catecholamine levels during perindopril therapy of chronic left ventricular failure in rats, 15
Howes L.G. & Krum H.: Plasma lipoproteins, cardiovascular reactivity and the sympathetic nervous system, 293
Howie C., *see* Elfellah M.S.

Jansakul C., Boura A.L.A. & King R.G.: Effects of endothelial cell removal on constrictor and dilator responses of aortae of pregnant rats, 93
Johnston C.I., *see* Howes L.G.

Kannisto P. & Owman Ch.: Prejunctional α-adrenoreceptors modulate the stimulated release of noradrenaline in isolated follicle strips from bovine ovaries, 411

Keith R.A., Mangano T.J., Pacheco M.A. & Salama A.I.: Characterization of the effects of ψ-conotoxin GVIA on the responses of voltage-sensitive calcium channels, 243
King R.G., *see* Jansakul C.
see also Rose'Meyer C.M.
Kopin I.J., *see* Szemeredi K.
Krantis A. & Krause C.: Interactions of the uclerogen cysteamine with enteric inhibitory nerves and putative transmitters in rat small intestine, 219
Krause C., *see* Krantis A.
Krum H., *see* Howes L.G.

Lawson K. & Cavero I.: Effects of Ca^{2+} antagonists and K^+-channel activation on K^+-induced contractions in the rat aorta, 315
Lefebvre R.A., *see* Barbier A.J.
Lonart G., Harsing L.G. Jr, Folly G. & Vizi E.S.: Failure of selective antagonists (CH-38083 and idazoxan) to distinguish between prejunctional and postjunctional α_2-adrenoreceptors, 149
Ludtke F.E., Golenhofen K. & Schubert F.: Angiotensin II stimulates human gastric smooth muscle *in vitro*, 139

McIntosh W., *see* Elfellah M.S.
McLenachan J.M., *see* Stott D.J.
Magee D.F.: The action of a β-adrenoreceptor agonist on gastric acid secretion in dogs, 183
Magee D.F., Naruse S. & Pap A.: A comparative study of gastric secretory stimulants in conscious dogs, 129
Magee D.F., *see also* Bennett L.
Maggi C.A., Santicioli P., Manzini S., Conti S., Giuliani S., Patacchini R. & Meli A.: Functional studies on the cholinergic and sympathetic innervation of the rat proximal urethra: effect of pelvic ganglionectomy or experimental diabetes, 231
Maggi C.A., *see also* Abelli L.
Malta E., *see* Ng N.L.
Mangano T.J., *see* Keith R.A.
Manzini S., *see* Maggi C.A.
Meghji S., *see* Draper A.J.
Meli A., *see* Abelli L.
see also Maggi C.A.
Muir T.C. & Wardle K.A.: Vascular smooth muscle responses in normo- and hypertensive rats to sympathetic nerve stimulation and putative transmitters, 23

Naruse S., *see* Bennett L.
see also Magee D.F.
Ng N.L. & Malta E.: Organ-bath studies using the irreversible β-adrenoreceptor antagonist bromoacetylalprenololmenthane (BAAM), 189
Nicholson C.D. & Wilke R.: 8-phenyltheophylline as an inhibitor of cyclic AMP hydrolysis by cyclic nucleotide phosphodiesterase, 159
Noronha-Blob L., *see* Peterson J.S.

Ornstein A.G., *see* Bond R.A.
Owman Ch., *see* Kannisto P.

Pacheco M.A., *see* Keith R.A.
Pap A., *see* Bennett L.
see also Magee D.F.
Parlani M., *see* Abelli L.
Patacchini R., *see* Maggi C.A.
Peterson J.S. & Noronha-Blob L.: Effects of selective cholinergic antagonists and α, β-methylene ATP on guinea-pig urinary bladder contractions *in vivo* following pelvic nerve stimulation, 303
Pirotzky E., *see* Delaflotte S.

Rand M.J., Story D.F. & Dowding T.: Examination of the paradoxical lack of responsiveness of the guinea-pig vas deferens to tyramine, 315
Rechnan M.P., *see* Rose'Meyer C.M.
Redfern P.H., *see* Draper A.J.
Regoli D., *see* Abelli L.
Reid J.L., *see* Elfellah M.S.
Robertson J.I.S., *see* Stott D.J.
Rose'Meyer C.P., Rechman M.P., Boura A.L.A. & King R.G.: Presynaptic α_2-adrenoreceptors affecting terminal synaptic transmission by the nervi cardiaci accelerantes in the rat, 119
Rovero P., *see* Abelli L.
Rowe P.R., *see* Howes L.G.

Salama A.I., *see* Keith R.A.
Santicioli P., *see* Maggi C.A.
Sauermelch C., *see* Willette R.N.
Schubert F., *see* Ludtke F.E.
Somma V., *see* Abelli L.
Story D.F., *see* Rand M.J.
Stott D.J., Robertson J.I.S., McLenachan J.M. & Ball S.G.: Effects of short-term ketanserin treatment on the QT interval and vagal function in healthy subjects, 45
Sumithran E., *see* Howes L.G.
Szemeredi K., Zukowska-Grojec Z., Bagdy G., Fekete M.I.K. & Kopin I.J.: Opposite effects of chronic cortisol treatment on pre- and post-synaptic actions of clonidine in pithed rats, 35

Theobald R.J. & de Groat W.D.: The effects of purine nucleotides on transmission in vesical parasympathetic ganglia of the cat, 167

Vila E., *see* Cuffi M.L.
Vizi E.S., *see* Lonart G.

Wardle K.A., *see* Muir T.C.
Wilke R., *see* Nicholson C.D.
Willette R.N., Sauermelch C. & Hieble J.P.: Stimulation of postjunctional alpha-1 and alpha-2 adrenoreceptors increases proximal urethral perfusion pressure in the pithed rat, 63
Wilson C.: Inhibition by sulphonylureas of vasorelaxation induced by K^+ channel activators *in vitro*, 71
Woodman O.L.: Noradrenaline-induced constriction of large and small coronary arteries in the anaesthetized dog, 53

Zukowska-Grojec Z., *see* Szemeredi K.

J. Auton. Pharmac. (1989), **9,** 433–435

Subject Index

Activators, potassium ion channel, 71, 329
Adrenaline, rabbit aorta, 337
Adrenergic drugs, plasma potassium, 133
Adrenoreceptor:
  agonist, 183
  antagonist, 149, 189
  blockade, 387
  corwin, 79
  heart, 265
  hypertensive rats, 103
  hypertrophied heart, 367
  muscle, 113
  plasma lipoproteins, 293
  prenalterol, 79
  presynaptic 119, 411
  selective antagonists, 149
  urethra, 63
Agonist:
  adrenoreceptor, 183, 293
  partial activity, 201
  tachykinin receptor, 53
AMP, cyclic, inhibitor, 159
ANF, aorta contraction, 211
Angiotensin, smooth muscle stimulation, 139
Antagonists:
  adrenoreceptor, 189, 265, 293
  calcium, 329
  cholinergic, 303
  selective, 149
Antipsychotic drugs, rat heart, 397
Aorta:
  contraction, 211, 329, 337
  endothelial cell removal, 93
Arteries, coronary, dog, 53
ATP:
  bladder contraction, 303
  vascular receptors, 357

BAAM, adrenoreceptor antagonist, 189
Bladder:
  contractions, 303
  tachykinins, 253

Calcium:
  antagonists, 329
  channels, conotoxin GVIA, 243
  dependent contraction, aorta, 211
Cardiovascular:
  catecholamine receptors, 397
  reactivity, 293
Cat, parasympathetic transmission, 167
Catecholamine:
  gastric secretion, 183
  heart hypertrophy, 367
  levels in heart, 15
  plasma lipoproteins, 293
  receptors, 397
CH-38083, adrenoreceptors, 149
Cholinergic:
  antagonists, 303
  innervation, 231
Chronotropic response, 387
Clonidine, rats, 35
Conotoxin GVIA, calcium channel response, 243
Constrictor response, aortae, 93
Contractions, potassium induced, 329
Control, secretion, 429
Cooling, noradrenaline release, 347
Coronary arteries, noradrenaline, 53
Cortisol, rats, 35
Corwin, adrenoreceptors, 79
Cow, ovary, adrenoreceptors, 411
Cyclic:
  AMP, inhibitor, 159
  nucleotide phosphodiesterase, 159
Cysteamine, small intestine, 219

DHPG, levels in heart, 15
Diabetes, innervation effects, 231
Dilator response, aortae, 93
Dog:
  arteries, noradrenaline, 53
  gastric secretion, 129, 183
  pancreas, isoprenaline, 379
Duodenum, guinea-pig, 279

Endothelial, removal effects on aortae, 93
Enteric inhibitory nerves, 219
Ethylenediamine, duodenum, 279

Facilitation, presynaptic, 103
Follicle, adrenoreceptors, 411

GABA, duodenum, guinea-pig, 279
Ganglia, vesical parasympathetic, 167
Ganglionectomy, pelvic, 231
Gastric:
  acid secretion, 183, 429
  pepsin, 429
  secretory stimulants, 129
  smooth muscle stimulation, 139
GR43175, partial agonistic activity, 201
Guinea-pig:
  bladder contractions, 303
  duodenum, 279
  vas deferens, tyramine, 315

Heart:
  accelerants, 199
  drug levels during therapy, 15
  hypertrophy, 367
  muscle *in vitro*, 387
  ventricle antagonists 265
Hydrolysis, cyclic AMP, 159
Hydroxy tryptamine, 3
Hypertension:
  adrenergic drugs, 113
  neurotransmission, 103
  smooth muscle, 23
Hypertrophy, heart, 367

Idazoxan, adrenoreceptors, 149
Inhibition:
  phosphodiesterase, 159
  presynaptic, 201
  sulphonylureas, 71
Innervation, urethra, 231
Inotropic response, 387
Isoprenaline:
  dog pancreas, 379
  rat heart, 265

Ketanserin, in healthy subjects, 45

Lipoproteins, plasma, 293

Mesenteric vasculature, noradrenaline, 347
Methylene ATP, 303, 357
Muscle:
  adrenoreceptors, 113
  responses to nerve stimulation, 23

Natriuretic factor, atrial, 211
Neurones, sympathetic, 3, 23, 231, 293, 367
Neurotransmission, hypertensive rats, 103
Noradrenaline:
  aorta, rabbit, 337
  coronary arteries, 53
  hypertrophied heart, 367
  mesenteric vasculature, 347
  ovary follicle, 411
Noradrenergic, neurones, 3
Nucleotides, purine, 167

Ovary, adrenoreceptors, 411

Pancreas, isoprenaline, 279
Parasympathetic, ganglia transmission, 167
Pelvic nerve stimulation, 303
Pepsin, secretion control, 429
Perindopril, heart therapy, 15
Permeability, vascular, 253
Phenylephrine, rat aorta, 211
Phenylethylene glycol, 3,4-dihydroxy levels in heart, 15
Phenyltheophylline, inhibitor, 159
Phosphodiesterase, cyclic nucleotide, 159
Plasma, lipoproteins, 293
Postsynaptic:
  adrenoreceptors, 63, 149
  clonidine action, 35
Potassium:
  adrenergic drugs, 113
  channel activators, 71, 329
Prenalterol, adrenoreceptors, 79
Presynaptic:
  adrenoreceptors, 119, 149, 411
  clonidine action, 35
  facilitation, hypertensive rats, 103
  5-HT-like receptor, 201
  tryptamine, 5-hydroxy, 3
Prinephritis, hypertension, rabbits, 113
Purine, nucleotides, 167

QT interval, ketanserin, 45

Rabbit:
  adrenoreceptors, 113
  aorta, 337
Rat:
  aorta, 93, 211, 329
  adrenoreceptors, 63, 119, 265
  cathecholamine receptors, 397
  cysteamine, 219
  heart muscle, 387
  kidney receptor, 201
  mesenteric vasculature, 347
  perindopril therapy, 15
  presynaptic facilitation, 103, 119
  smooth muscle, 23
  tachykinins, 253
  urethral innervation, 231
  vascular receptors, 357
  ventricle, 265
Receptors:
  catecholamine, 397
  5-HT, 3, 201
  NK-1, 253
  P_{2x}, 357
  tachykinin agonists, 253

Secretion:
gastric acid, 183, 429
pepsin, 429
Secretory stimulants, gastric, 129
Stimulants:
gastric secretory, 129
smooth muscle, 139
Stomach, angiotensin, 139
Sulphonylurea, inhibition of vasorelaxation, 71
Suramin, vascular receptors, 357
Sympathetic neurones, 3, 23, 293, 231, 367

Tachykinins, vascular permeability, 253
Transmission:
adrenaline, 337
parasympathetic ganglia, 167
terminal synapse, 119
Transmitters, smooth muscle, 23, 219
Tryptamine, 5-hydroxy, 3, 201
Tyramine, vas deferens, 315

Urethra:
adrenal receptors, 63
innervation, 231
tachykinins, 253

Vagal function, ketanserin, 45
Vas deferens, tyramine response, 315
Vascular responses:
hypertension, 23
lipoproteins, 293
plasma proteins, 293
tachykinins, 253
Vasoconstriction, coronary arteries, 53
Vasorelaxation, inhibition, 71
Ventricular failure, rat, 15
Voltage-sensitive, calcium channels, 243